Publications by authors named "Per Omvik"

Claim this Profile
C
Contrasting hemodynamic mechanisms of losartan- vs. atenolol-based antihypertensive treatment: a LIFE study.
Anders M Greve, Michael H Olsen, Jonathan N Bella, Mai T Lønnebakken, Eva Gerdts, Per Omvik

Am J Hypertens· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in subclinical organ damage vs. in Framingham risk score for assessing cardiovascular risk reduction during continued antihypertensive treatment: a LIFE substudy.
Michael H Olsen, Kristian Wachtell, Hans Ibsen, Lars Lindholm, Sverre E Kjeldsen, Per Omvik

J Hypertens· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Sverre E Kjeldsen, Richard B Devereux, Darcy A Hille, Paulette A Lyle, Björn Dahlöf, Per Omvik

Blood Press· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left ventricular long-axis function in treated haemochromatosis.
Einar Skulstad Davidsen, Tor Hervig, Per Omvik, Eva Gerdts

Int J Cardiovasc Imaging· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Michael Hecht Olsen, Kristian Wachtell, Gareth Beevers, Björn Dahlöf, Giovanni de Simone, Per Omvik

J Hypertens· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left ventricular diastolic function in patients with treated haemochromatosis.
Einar Skulstad Davidsen, Per Omvik, Tor Hervig, Eva Gerdts

Scand Cardiovasc J· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.
Michael Hecht Olsen, Kristian Wachtell, Gareth Beevers, Björn Dahlöf, Richard B Devereux, Per Omvik

Am Heart J· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population.
Tonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, Per Omvik, Tsushung A Hua

Hypertension· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced exercise capacity in genetic haemochromatosis.
Einar Skulstad Davidsen, Knut Liseth, Per Omvik, Tor Hervig, Eva Gerdts

Eur J Cardiovasc Prev Rehabil· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Eva Gerdts, Kristian Wachtell, Per Omvik, Jan Erik Otterstad, Lasse Oikarinen

Hypertension· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Richard B Devereux, Ulf de Faire, Frej Fyhrquist, Katherine E Harris, Hans Ibsen, Per Omvik

Curr Med Res Opin· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy).
Eva Gerdts, Hans Björnstad, Richard B Devereux, Per Lund-Jhansen, Einar S Davidsen, Per Omvik

Blood Press· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Sverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, Richard B Devereux, Suzanne Oparil, Per Omvik

Expert Opin Emerg Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Eigil Fossum, Andreas Moan, Sverre E Kjeldsen, Richard B Devereux, Stevo Julius, Per Omvik

J Am Coll Cardiol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Henrik M Reims, Suzanne Oparil, Sverre E Kjeldsen, Richard B Devereux, Stevo Julius, Per Omvik

Blood Press· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Frej Fyhrquist, Björn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, Stevo Julius, Per Omvik

Hypertension· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
Giovanni de Simone, Kristian Wachtell, Vittorio Palmieri, Darcy A Hille, Gareth Beevers, Per Omvik

Circulation· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Sverre E Kjeldsen, Paulette A Lyle, Jorge R Kizer, Björn Dahlöf, Richard B Devereux, Per Omvik

J Clin Hypertens (Greenwich)· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Hans Ibsen, Michael H Olsen, Kristian Wachtell, Knut Borch-Johnsen, Lars H Lindholm, Per Omvik

Hypertension· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Jorge R Kizer, Björn Dahlöf, Sverre E Kjeldsen, Stevo Julius, Gareth Beevers, Per Omvik

Hypertension· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Hans Ibsen, Kristian Wachtell, Michael H Olsen, Knut Borch-Johnsen, Lars H Lindholm, Per Omvik

J Hypertens· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians.
Eva M Staal, Ottar K Nygård, Per Omvik, Eva Gerdts

Blood Press Monit· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Why not always diuretics?].
Per Omvik, Per Lund-Johansen

Tidsskr Nor Laegeforen· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment of hypertension in patients with left ventricular hypertrophy].
Per Omvik, Bjørn Bratland, Gerhard Gerhardsen, Kjell Gisholt, Terje Risanger

Tidsskr Nor Laegeforen· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Hypertension and heart disease].
Eva Gerdts, Per Omvik, Rune Mo, Sverre E Kjeldsen

Tidsskr Nor Laegeforen· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis